Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Vicuron Pharmaceuticals to Present at the Pacific Growth Equities
Conference
KING OF PRUSSIA, Pa., June 7 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals
Inc. (NASDAQ:MICU) today announced that Dov A. Goldstein, M.D., Executive Vice
President and CFO, will present at the Pacific Growth Equities Life Sciences
Conference at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) on Wednesday,
June 9, 2004 at The Mark Hopkins Inter-Continental Hotel in San Francisco,
Calif.
To access the live audio broadcast or the subsequent archived recording log on
to http://www.vicuron.com/ and click on the investor relations section. Please
connect to the website several minutes prior to the start of the webcast to
ensure adequate time for any software download that may be necessary. The live
broadcast will be archived for 30 days.
About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients in North America and Europe. The company received an approvable letter
for its lead product anidulafungin in May 2004. The company's other lead
product, dalbavancin, a novel intravenous antibiotic for the treatment of
serious Gram-positive infections, is in Phase III clinical trials. The
company's versatile research engine integrates industry-leading expertise in
functional genomics, natural products discovery, mechanism-based drug design
and combinatorial and medicinal chemistry. These approaches are yielding
promising novel and next-generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has research and
development collaborations with leading pharmaceutical companies, such as
Pfizer and Novartis.
Forward-Looking Statements
This news release and the presentation contain forward-looking statements that
predict or describe future events or trends. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are beyond
Vicuron's control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that clinical trials
and the results thereof might be delayed, that the timing of the filing of any
new drug application might be delayed, that subsequent clinical trials might
indicate that a product candidate is unsafe or ineffective, that any filed new
drug application may not be approved, that ongoing proprietary and
collaborative research might not occur or yield useful results, that a third
party may not be willing to license our product candidates on terms acceptable
to us or at all, that competitors might develop superior substitutes for their
products or market them more effectively, that a sales force may not be
developed as contemplated and that one or more of its product candidates may
not be commercialized successfully. The reports that Vicuron files with the
U.S. Securities and Exchange Commission contain a fuller description of these
and many other risks to which Vicuron is subject. Because of those risks,
Vicuron's actual results, performance or achievements may differ materially
from the results, performance or achievements contemplated by its forward-
looking statement. The information set forth in this news release and the
presentation represent management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the forward-looking
matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Jeffrey S. Tarmy, +1-617-939-3316, or
, for Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/